Intranasal ketamine (esketamine) or Spravato offers a new path for people who have not found relief with traditional treatments for depression and other mood disorders. Carefully monitored nasal-spray protocols are becoming more accessible as a treatment option. They act quickly, integrate smoothly into structured mental-health programs, and support recovery in a compassionate, clinically rigorous setting. This guide explains what intranasal ketamine is, who might qualify, what treatment involves, and what to expect.
What Intranasal Ketamine Involves
Intranasal ketamine refers to a nasal-spray form of ketamine, most often delivered as esketamine (Spravato), a molecule related to standard ketamine but used specifically for mental-health treatment. Instead of an intravenous infusion, the medication is offered through the nasal lining, where it is absorbed into the bloodstream.
Clinics use this medication under strict medical oversight. Many patients prefer it because it avoids needles, allows structured dosing, and fits within a tightly regulated treatment pathway. Compared with IV ketamine, the nasal route offers lower bioavailability but a similar potential to relieve symptoms, especially for people who have struggled for years without improvement.
Who is Intranasal Ketamine for?
Most programs limit access to individuals who meet criteria for treatment-resistant depression (TRD). TRD usually means a patient has tried at least two antidepressants at effective dosages without meaningful relief.
Clinics may also offer intranasal ketamine for:
- Major depressive disorder with suicidal thoughts, when previous treatments have not worked
- Severe or rapidly worsening depressive episodes, where a fast-acting option is clinically appropriate
Clinicians also look for medical reasons why someone might not be a good fit, because intranasal ketamine affects the whole body. People with very high blood pressure, certain heart or brain conditions, or a history of psychosis may need a different option. Substance-use issues, liver problems, or pregnancy can also change eligibility. The aim is to keep treatment safe, steady, and well-supported.
What a Treatment Plan Looks Like
Expect a highly structured process that protects your safety at every step. A typical plan usually includes:
1. Initial evaluation
A psychiatrist or psychiatric nurse practitioner meets with the patient to review medical history, discuss goals, review prior treatments, and confirm whether nasal ketamine meets their needs. This evaluation also clarifies expectations and creates space for questions about risks, potential gains, and the emotional impact of treatment.
2. Program enrollment
Because esketamine requires specific oversight, clinics follow protocols similar to federal RREMS requirements: controlled access, onsite monitoring, and staff trained in managing dissociation, blood pressure changes, and mood shifts. Patients cannot pick up this medication at a pharmacy; all doses occur under supervision.
3. Dosing schedule
A standard course often begins with twice-weekly doses for several weeks. This induction phase establishes therapeutic momentum. If a patient responds, sessions are gradually spaced out to once weekly and eventually every one to two weeks. The maintenance phase adjusts as symptoms change over the course of treatment and life circumstances evolve.
4. Ongoing monitoring
Vital signs, mood, thought patterns, and overall functioning are closely monitored throughout treatment. Clinicians capture changes in symptoms, sleep, appetite, suicidality, and cognitive clarity. Adjustments follow evidence, and maintaining a responsively adapted structure helps patients feel held, informed, and supported.
What to Expect During and After a Session
A session typically unfolds with clarity and calm. Patients arrive, check in, and sit in a comfortable room designed for quiet focus.
Administration
A clinician guides the patient through self-administering the nasal spray, usually with two sprays directed into each nostril. Each device contains a single dose. The team confirms correct use and checks vital signs before the experience begins.
Clinics often request that patients avoid food for two hours and drinks for about 30 minutes before sessions to reduce nausea.
During the session
As the medication takes effect, many patients notice a shift in perception: spaciousness, lightness, distance from painful thoughts, or a softened experience of distress. Some describe a sense of mental reset: a pause in the usual cycle of rumination. Staff monitor blood pressure, coordination, and cognitive status, and offer reassurance as needed.
Dissociation may occur, but supervisors will always help a person attending an intranasal ketamine session frame it as a temporary and manageable effect.
After the session
Most programs require patients to remain in the clinic for at least two hours. This observation window ensures safe recovery and stable vital signs. Because reaction time may remain impaired for the rest of the day, patients arrange transportation home and spend the remainder of the day resting.
Potential Side Effects of Intranasal Ketamine
Intranasal ketamine has a strong safety record when administered under the supervision of trained professionals. Still, it affects multiple systems and requires informed decision-making.
Common short-term effects
- Temporary dissociation
- Dizziness or unsteady sensation
- Nausea
- Elevated blood pressure
- Headache
- Altered perception
- Nasal discomfort or irritation
These effects usually fade within 1–2 hours.
Less common or long-term considerations
Repeated, unmanaged ketamine use outside of clinical settings can affect bladder function, cognition, or addiction pathways. Supervised programs significantly reduce these risks because dosing remains limited, structured, and medically justified.
Supervised treatment also involves monitoring blood pressure, thought patterns, and symptom changes over time and adjusting treatment if any concerning signs appear. The goal is to keep the process transparent: patients know the risks, see the safety measures in place, and feel empowered to ask questions.
Comparative Context: Intranasal vs IV Ketamine
Both intranasal and IV ketamine can support people with treatment-resistant depression. Each route conveys unique strengths:
Intranasal advantages
- No needles
- Faster sessions
- Lower cost in many clinics
- Strong regulatory structure
- Predictable, standardized dosing
IV advantages
- Higher bioavailability
- Faster onset for some patients
- Greater flexibility with dose titration
Many patients appreciate the gentler onset of the nasal route, while others prefer the precision of IV infusions. Clinicians guide patients according to medical needs, personal comfort, and documented response patterns.
How Intranasal Ketamine Feels in the Body
Intranasal esketamine (Spravato) often feels like entering a brief, dream-like state. Many people describe a soft sense of detachment or “floatiness,” as though their body and thoughts drift slightly apart.
Sensations after dosing with intranasal ketamine can include:
- Light dizziness
- Mild visual or sensory shifts
- Subtle brightness
- A sense of space
- Calmness or emotional lightness
- A loosening of intense mental pain or pressure
Some experience mild nausea, slight disorientation, or internal “buzz.” A majority of these effects fade within one to two hours under medical supervision; afterward, many report a clearer head, a softer mood, and a sense of relief from a heavy emotional burden.
Patient Support Framework
High-quality clinics position intranasal ketamine within a comprehensive mental-health program. Patients receive care that involves:
Therapeutic integration
Clinicians encourage patients to process emotional shifts with therapists trained in depression, trauma, or anxiety. Therapy helps patients anchor breakthroughs, track triggers, and identify new patterns emerging from treatment.
Psychiatric oversight
Regular check-ins allow medication adjustments, dosage changes, and ongoing risk assessment. This ensures safety while maintaining treatment momentum.
Coordinated services
Some clinics also provide access to complementary supports such as psychiatry groups, stress-management tools, or technology-assisted therapies when appropriate. The goal is full-spectrum care; a structure that surrounds the patient with consistent, compassionate attention.
Family or community support
Patients may receive guidance speaking with loved ones about treatment, planning for days with post-session fatigue, and creating stable routines at home. This framework improves outcomes because ketamine works best when paired with relational support, mental-health structure, and ongoing follow-through.
Part of a Broader Ecosystem of Care
Intranasal ketamine offers meaningful relief for many, but it remains one part of a larger mental-health landscape.
Limitations of intranasal ketamine as a standalone treatment include:
- Not every patient responds.
- Some experience partial or temporary improvement.
- Programs must monitor blood pressure, dissociation, and mood changes at every visit.
- Relief often depends on ongoing support, structured therapy, and improving one’s broader life context.
Patients benefit most when they approach intranasal ketamine as one treatment pathway in their larger ecosystem of healthcare, not a solo therapy.
Key Takeaways
- Relief: Intranasal ketamine offers a fast-acting option for people with treatment-resistant depression.
- Protocol: Treatment follows a structured, supervised clinical plan.
- Sessions: Each includes dosing, observation, and next-day recovery.
- Side effects: Usually remain temporary and manageable.
- Support: Mental-health care systems enhance treatment success.
- Safety: Screening determines patient eligibility.
FAQs
Q: Who might benefit from intranasal ketamine?
A: People with treatment-resistant depression or major depression with suicidal thoughts may qualify if they meet safety criteria and work with a supervised clinical program.
Q: How long does a typical session last?
A: A session usually includes short pre-dose checks, nasal administration, and about two hours of monitoring. Most patients leave the clinic the same day and rest at home.
Q: Does intranasal ketamine replace therapy or other medications?
A: No. Intranasal ketamine is usually integrated into a broader plan involving therapy, psychiatric support, and lifestyle care. Many patients continue previous medications unless clinicians advise a change.
Q: Does intranasal ketamine combine with transcranial magnetic stimulation (TMS)?
A: TMS and ketamine may work synergistically for treatment-resistant depression. TMS targets mood-related neural circuits while ketamine boosts rapid neuroplasticity. Early studies show greater symptom reduction and longer-lasting relief than either treatment alone, with generally mild, temporary side effects, though larger controlled trials are still needed.